Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01518920 · ClinicalTrials.gov registry record · Phase 1

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

A Phase 1 study, sponsored by Biogen.

Completed
Registry status
Phase 1
Development phase
44
Enrollment target

NCT01518920: Completed Phase 1 study, sponsored by Biogen.

NCT01518920 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 44 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01518920, a Phase 1 study, has completed, sponsored by Biogen.

COMPLETED
Registry status
Phase 1
Development phase
44 participants
Enrollment target

Study Summary

The objective of this study is to examine the safety, tolerability, and effects on hearing thresholds of two single doses of PF-04958242 and placebo in subjects with age-related hearing loss.

Interventions

  • DRUG Placebo
  • DRUG PF-04958242

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2011-12
Est. Completion 2013-02
Phase Phase 1
Biogen

334 total trials

What the finished NCT01518920 record still lists

NCT01518920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01518920 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01518920 about?

NCT01518920 is a clinical study titled "A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss". The objective of this study is to examine the safety, tolerability, and effects on hearing thresholds of two single doses of PF-04958242 and placebo in subjects with age-related hearing loss.

What is the current status of trial NCT01518920?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2011-12. Estimated completion is 2013-02.

What interventions are being tested in trial NCT01518920?

The interventions under investigation include: Placebo (DRUG), PF-04958242 (DRUG).

Who is sponsoring clinical trial NCT01518920?

This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01518920's enrollment target sits among peer trials

44 1086th of 2000 higher than 901 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01518920, the US trial registry maintained by the National Library of Medicine. NCT01518920 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.